Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics

OncoImmunology

Nicole Rufo¹  Odeta Mece¹  Sanket More¹  Abhishek D. Garg¹  Maria Livia Sassano¹  Patrizia Agostinis¹  Laurence Zitvogel²  Lorenzo Galluzzi³  Guido Kroemer³ 

[1] Cell Death Research & Therapy (CDRT) Lab;Gustave Roussy Comprehensive Cancer Institute;Université Paris Descartes/Paris V;

关键词: antigen-presenting cell;    autophagy;    cytotoxic t lymphocyte;    endoplasmic reticulum stress;    damage-associated molecular pattern;    dendritic cell;    immune checkpoint blocker;    type i interferon;   

DOI  :  10.1080/2162402X.2017.1386829

来源: DOAJ

【 摘 要 】

The expression “immunogenic cell death” (ICD) refers to a functionally unique form of cell death that facilitates (instead of suppressing) a T cell-dependent immune response specific for dead cell-derived antigens. ICD critically relies on the activation of adaptive responses in dying cells, culminating with the exposure or secretion of immunostimulatory molecules commonly referred to as “damage-associated molecular patterns”. Only a few agents can elicit bona fide ICD, including some clinically established chemotherapeutics such as doxorubicin, epirubicin, idarubicin, mitoxantrone, bleomycin, bortezomib, cyclophosphamide and oxaliplatin. In this Trial Watch, we discuss recent progress on the development of ICD-inducing chemotherapeutic regimens, focusing on studies that evaluate clinical efficacy in conjunction with immunological biomarkers.

【 授权许可】

Unknown